Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 38, 3817-3822, November 1, 1978]
© 1978 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eiselein, J. E.
Right arrow Articles by Walton, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eiselein, J. E.
Right arrow Articles by Walton, J. R.

Treatment of Transplanted Murine Tumors with an Oncolytic Virus and Cyclophosphamide1

John E. Eiselein2, Max W. Biggs and Judie R. Walton

Medical Department, Lawrence Livermore Laboratory, University of California, Livermore, California 94550

Effective treatment of transplanted murine mammary tumors with an oncolytic virus and cyclophosphamide is reported. The oncolytic virus was cultured initially from a murine ascites tumor that had undergone "spontaneous" regression. This virus used alone causes rapid lysis of ascites tumors, but successful treatment of solid tumors requires the addition of cyclophosphamide. The virus must be injected directly into the tumor.

The virus causes no detectable disease in mice even when administered in conjunction with cyclophosphamide. Fluorescent antibody techniques revealed that all A/S stock mice have antibody against cells infected with this virus.

1 This work was performed under the auspices of the United States Department of Energy by Lawrence Livermore Laboratory under Contract W-7405-Eng-48.

2 To whom requests for reprints should be addressed, at Medical Department, Lawrence Livermore Laboratory, University of California, P.O. Box 808, Livermore, Calif. 94550.

Received 4/11/78. Accepted 8/ 8/78.




This article has been cited by other articles:


Home page
JNCI J Natl Cancer InstHome page
K. Kurozumi, J. Hardcastle, R. Thakur, M. Yang, G. Christoforidis, G. Fulci, F. H. Hochberg, R. Weissleder, W. Carson, E. A. Chiocca, et al.
Effect of Tumor Microenvironment Modulation on the Efficacy of Oncolytic Virus Therapy
J Natl Cancer Inst, December 5, 2007; 99(23): 1768 - 1781.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1978 by the American Association for Cancer Research.